Inventor · disambiguated record
Yi Liu
Also filed as: LIU YI · LIU YI-TSUNG
168 granted patents·70 pending applications·3,212 citations·filing 1980–2025
99Inventor score
Top patents by PatentIndex Score
238 records- 0198US10144724B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Dec 4, 2018·44 cites·42 claims
- 0298US9810690B2Method for screening inhibitors of RasARAXES PHARMA LLC·Filed 2016·Granted Nov 7, 2017·41 cites·30 claims
- 0398US8569323B2Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereofREN PINGDA·Filed 2012·Granted Oct 29, 2013·61 cites·14 claims
- 0498US8193182B2Substituted isoquinolin-1(2H)-ones, and methods of use thereofREN PINGDA·Filed 2009·Granted Jun 5, 2012·93 cites·39 claims
- 0597US10745385B2Covalent inhibitors of KRASARAXES PHARMA LLC·Filed 2018·Granted Aug 18, 2020·17 cites·54 claims
- 0697US10646488B2Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereofARAXES PHARMA LLC·Filed 2017·Granted May 12, 2020·22 cites·16 claims
- 0797US10377743B2Inhibitors of RAS and methods of use thereofARAXES PHARMA LLC·Filed 2017·Granted Aug 13, 2019·29 cites·31 claims
- 0897US10370386B2Substituted quinolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2017·Granted Aug 6, 2019·33 cites·30 claims
- 0997US10351550B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Jul 16, 2019·27 cites·32 claims
- 1097US10246424B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Apr 2, 2019·36 cites·90 claims
- 1197US9926267B2Covalent inhibitors of K-Ras G12CARAXES PHARMA LLC·Filed 2015·Granted Mar 27, 2018·38 cites·35 claims
- 1297US9862701B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2015·Granted Jan 9, 2018·45 cites·18 claims
- 1397US9840516B2Substituted quinazolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2014·Granted Dec 12, 2017·73 cites·33 claims
- 1497US9745319B2Irreversible covalent inhibitors of the GTPase K-Ras G12CARAXES PHARMA LLC·Filed 2014·Granted Aug 29, 2017·43 cites·11 claims
- 1597US9359349B2Substituted quinazolines as kinase inhibitorsINTELLIKINE LLC·Filed 2014·Granted Jun 7, 2016·56 cites·9 claims
- 1697US9315505B2Heterocyclic compounds and uses thereofINTELLIKINE LLC·Filed 2014·Granted Apr 19, 2016·64 cites·18 claims
- 1797US9227978B2Covalent inhibitors of Kras G12CARAXES PHARMA LLC·Filed 2014·Granted Jan 5, 2016·47 cites·24 claims
- 1897US9181221B2Chemical compounds, compositions and methods for kinase modulationINFINITY PHARMACEUTICALS INC·Filed 2013·Granted Nov 10, 2015·64 cites·18 claims
- 1997US9096611B2Kinase inhibitors and methods of useREN PINGDA·Filed 2009·Granted Aug 4, 2015·65 cites·11 claims
- 2097US8785470B2Heterocyclic compounds and uses thereofCASTRO ALFREDO C·Filed 2012·Granted Jul 22, 2014·41 cites·24 claims
- 2197US8604032B2Chemical compounds, compositions and methods for kinase modulationREN PINGDA·Filed 2011·Granted Dec 10, 2013·48 cites·42 claims
- 2297US7012066B2Peptides as NS3-serine protease inhibitors of hepatitis C virusDENDREON CORP·Filed 2001·Granted Mar 14, 2006·176 cites·64 claims
- 2396US11912708B2Macrocyclic heterocycles and uses thereofKUMQUAT BIOSCIENCES INC·Filed 2023·Granted Feb 27, 2024·5 cites·30 claims
- 2496US11648254B2Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signalingKUMQUAT BIOSCIENCES INC·Filed 2022·Granted May 16, 2023·7 cites·30 claims
- 2596US10927125B2Substituted cinnolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2019·Granted Feb 23, 2021·11 cites·29 claims
- 2696US10919850B2Covalent inhibitors of KRas G12CARAXES PHARMA LLC·Filed 2019·Granted Feb 16, 2021·9 cites·38 claims
- 2796US10858343B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Dec 8, 2020·11 cites·15 claims
- 2896US10829458B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2019·Granted Nov 10, 2020·13 cites·29 claims
- 2996US10730867B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Aug 4, 2020·15 cites·19 claims
- 3096US10723738B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2019·Granted Jul 28, 2020·15 cites·22 claims
- 3196US10689356B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Jun 23, 2020·16 cites·15 claims
- 3296US10414757B22-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Sep 17, 2019·33 cites·49 claims
- 3396US10280172B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2017·Granted May 7, 2019·34 cites·19 claims
- 3496US10273207B2Covalent inhibitors of kras G12CARAXES PHARMA LLC·Filed 2018·Granted Apr 30, 2019·24 cites·34 claims
- 3596US10077271B2Methods and compositions for inhibiting the interaction of menin with MLL proteinsKURA ONCOLOGY INC·Filed 2017·Granted Sep 18, 2018·14 cites·18 claims
- 3696US9085560B2Heterocyclic compounds and uses thereofREN PINGDA·Filed 2010·Granted Jul 21, 2015·37 cites·12 claims
- 3796US8969363B2Heterocyclic compounds and uses thereofCASTRO ALFREDO C·Filed 2012·Granted Mar 3, 2015·44 cites·56 claims
- 3896US8940742B2Heterocyclic compounds and uses thereofINFINITY PHARMACEUTICALS INC·Filed 2013·Granted Jan 27, 2015·35 cites·48 claims
- 3996US8901133B2Heterocyclic compounds and uses thereofREN PINGDA·Filed 2011·Granted Dec 2, 2014·44 cites·54 claims
- 4096US8785456B2Substituted isoquinolin-1(2H)-ones, and methods of use thereofREN PINGDA·Filed 2012·Granted Jul 22, 2014·25 cites·170 claims
- 4196US8703777B2Certain chemical entities, compositions and methodsREN PINGDA·Filed 2009·Granted Apr 22, 2014·36 cites·35 claims
- 4296US7642255B2Compounds and compositions as protein kinase inhibitorsIRM LLC·Filed 2008·Granted Jan 5, 2010·60 cites·6 claims
- 4396US6800434B2Peptides as NS3-serine protease inhibitors of hepatitis C virusSCHERING CORP·Filed 2001·Granted Oct 5, 2004·89 cites·1 claims
- 4496US6440974B2Compounds useful for inhibition of farnesyl protein transferaseSCHERING CORP·Filed 2001·Granted Aug 27, 2002·53 cites·9 claims
- 4595US12286427B2Heterocyclic compounds and uses thereofKUMQUAT BIOSCIENCES INC·Filed 2024·Granted Apr 29, 2025·3 cites·20 claims
- 4695US10736897B2Compounds and methods of use thereof for treatment of cancerARAXES PHARMA LLC·Filed 2018·Granted Aug 11, 2020·28 cites·15 claims
- 4795US10428064B2Fused-tricyclic inhibitors of KRAS and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Oct 1, 2019·27 cites·28 claims
- 4895US10111874B2Combination therapies for treatment of cancerARAXES PHARMA LLC·Filed 2015·Granted Oct 30, 2018·39 cites·20 claims
- 4995US10011600B2Methods and compositions for inhibition of RasARAXES PHARMA LLC·Filed 2015·Granted Jul 3, 2018·12 cites·21 claims
- 5095US9127000B2Heterocyclic compounds and uses thereofREN PINGDA·Filed 2012·Granted Sep 8, 2015·30 cites·9 claims
Showing the top 50 of 238 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Yi Liu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →